NCT04945616View on ClinicalTrials.gov

To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

October 19, 2021

Study Completion Date

June 15, 2022

Conditions
Thrombosis
Interventions
DRUG

Aspirin、clopidogrel、placebo or SHR2285

groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；

DRUG

Aspirin、clopidogrel、placebo or SHR2285

groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)

DRUG

Aspirin、ticagrelor、placebo or SHR2285

groupC： Aspirin + ticagrelor + placebo or SHR2285

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY